# Lakewood-Amedex Biotherapeutics Inc.: overview

LABT · Nasdaq · CIK 2079272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/labt.md) · [Financials](/companies/labt/financials.md) · [Filings](/companies/labt/filings.md) · [Insiders](/companies/labt/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.15)](/filings/0001213900-26-060640.md) | [(1.66)](/filings/0001213900-26-089380.md) | [(0.20)](/filings/0001213900-26-060640.md) | [(2.75)](/filings/0001213900-26-089380.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/labt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Marex Group Ltd](/funds/1997464.md) | 2026-06-30 | $151.2k | 48,167 |  | New +48,167 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $12.9k | 4,098 |  | New +4,098 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.0k | 624 |  | New +624 |
| [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $433 | 138 |  | New +138 |
| [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $140 | 44,782 |  | New +44,782 |
| [Blue Trust, Inc.](/funds/1856022.md) | 2026-06-30 | $35 | 11 |  | New +11 |

## Recent filings

[All 44 filings](/companies/labt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-29 | 17:49 ET | [8-K](/filings/0001213900-26-104177.md) | 5.07 Shareholder vote results | 0001213900-26-104177 |
| 2026-09-18 | 17:30 ET | [S-1](/filings/0001213900-26-101512.md) | Registration statement | 0001213900-26-101512 |
| 2026-08-14 | 21:36 ET | [10-Q](/filings/0001213900-26-089380.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089380 |
| 2026-08-10 | 17:13 ET | [DEF 14A](/filings/0001213900-26-087336.md) | Proxy statement, period 2026-09-22 | 0001213900-26-087336 |
| 2026-07-15 | 16:15 ET | [8-K](/filings/0001213900-26-078328.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-078328 |
| 2026-06-17 | 11:40 ET | [8-K](/filings/0001213900-26-069512.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-26-069512 |
| 2026-05-22 | 16:55 ET | [10-Q](/filings/0001213900-26-060640.md) | Quarterly report, period 2026-03-31 | 0001213900-26-060640 |
| 2026-05-01 | 16:05 ET | [S-1](/filings/0001213900-26-050936.md) | Registration statement | 0001213900-26-050936 |
| 2026-04-28 | 16:15 ET | [8-K](/filings/0001213900-26-048553.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-048553 |
| 2026-04-06 | 11:38 ET | [S-1/A](/filings/0001213900-26-040254.md) | Registration statement, amended | 0001213900-26-040254 |

## Latest annual report

No annual report is in coverage.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2079272
- Tickers: LABT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NV
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.